CA-PEGASUS-TECH
10.3.2021 13:02:13 CET | Business Wire | Press release
Pegasus Tech Ventures (“Pegasus”), a global venture capital firm based in Silicon Valley, announced a partnership with Japan’s television shopping giant Japanet Holdings (“Japanet”) to establish a $50 million corporate venture capital fund to invest in innovative startups around the globe.
Japanet, headquartered in Nagasaki, Japan, is well-known for its home shopping services and now is expanding into other business sectors. The company recently started a new project to build “Stadium City” in Nagasaki, Japan, which will open in 2024. Centered on a sports stadium, the project includes the development of mixed-use facilities such as business offices, retail stores, hotels, and live event arenas, aiming to make it a Nagasaki landmark that will revitalize the local and regional community. Japanet is also committed to the enrichment of elderly life and to providing educational support for children around the globe.
Through the fund with Pegasus, Japanet aims to create value by funding new ideas and collaborating with startups that develop innovative technologies. The fund plans to invest in Silicon Valley and other parts of North America, as well as in Israel, Europe and Asia.
“We at Japanet Group would like to find high-potential startups with talented entrepreneurs and help them succeed and contribute real value to the world. Using a venture fund, we would like to find cutting edge startup technologies that we can use in the Nagasaki 'Stadium City' project, so that we can provide new services, such as child education, elder care, hospitality, and other services that can help with the betterment of people’s lives,” said Akito Takata, President and CEO of Japanet.
"We will leverage our global network to introduce Japanet to top-tier startups,” said Anis Uzzaman, Founder and CEO of Pegasus Tech Ventures. “By making the connection, both the startups and Japanet benefit. Our goal is to create a global innovation platform that supports the growth of our portfolio companies and the success of our corporate partners.”
Pegasus will deploy its team in Silicon Valley and in 15 other regions around the world to find the best startups and connect them with Japanet and Pegasus’ extensive network of corporate partners.
Pegasus has established venture investment funds with over 35 global corporations, including Aisin Seiki, Sojitz Corporation, SEGA SAMMY HOLDINGS, Sunny Health, CAC Holdings Corporation, Teijin Limited, Infocom Corporation, Innotech Corporation, and ASUS, among others.
About Japanet Holdings Co., Ltd.
Based on a corporate vision, "The joy of living now," Japanet operates a home shopping business, as well as a major sports related business designed to revitalize the local and regional community. In order to enrich the "now," Japanet is also working to enhance healthcare services and to address other social issues, such as educational support for children around the world, and support for disaster-stricken areas. For more information, please visit the website https://corporate.japanet.co.jp/ .
About Pegasus Tech Ventures
Pegasus Tech Ventures is a global venture capital firm based in Silicon Valley with $1.5 Billion in Assets Under Management. Pegasus offers intellectual and financial capital to emerging technology companies around the world. In addition to offering institutional investors a top-tier venture capital investment approach, Pegasus also offers a unique Venture Capital-as-a-Service (VCaaS) model for large, global corporations that wish to partner with cutting-edge technology startups. Some of the 35+ corporate partners that have signed up to work with Pegasus include ASUS, Aisin, SEGA, Sojitz, and Omron. These corporations are able to have access to 180+ Pegasus portfolio companies such as SpaceX, 23andMe, SoFi, Bird, Color, App Annie, and many more. To learn more, visit www.pegasustechventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005135/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom